iRadimed (IRMD) Competitors

iRadimed logo
$84.84 -0.51 (-0.60%)
Closing price 04:00 PM Eastern
Extended Trading
$84.90 +0.06 (+0.08%)
As of 07:32 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

IRMD vs. ITGR, PLSE, TMDX, AXGN, and ATRC

Should you buy iRadimed stock or one of its competitors? iRadimed's main competitors and comparable companies include Integer (ITGR), Pulse Biosciences (PLSE), TransMedics Group (TMDX), AxoGen (AXGN), and AtriCure (ATRC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does iRadimed compare to Integer?

Integer (NYSE:ITGR) and iRadimed (NASDAQ:IRMD) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, valuation, profitability, risk and dividends.

In the previous week, Integer and Integer both had 2 articles in the media. Integer's average media sentiment score of 1.88 beat iRadimed's score of 1.79 indicating that Integer is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Integer
2 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive
iRadimed
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive

Integer has higher revenue and earnings than iRadimed. Integer is trading at a lower price-to-earnings ratio than iRadimed, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Integer$1.85B2.32$102.81M$2.9842.50
iRadimed$83.81M13.03$22.48M$1.8745.64

Integer has a beta of 0.6, indicating that its stock price is 40% less volatile than the broader market. Comparatively, iRadimed has a beta of 0.91, indicating that its stock price is 9% less volatile than the broader market.

99.3% of Integer shares are owned by institutional investors. Comparatively, 92.3% of iRadimed shares are owned by institutional investors. 1.1% of Integer shares are owned by company insiders. Comparatively, 34.6% of iRadimed shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

iRadimed has a net margin of 26.85% compared to Integer's net margin of 5.68%. iRadimed's return on equity of 23.90% beat Integer's return on equity.

Company Net Margins Return on Equity Return on Assets
Integer5.68% 11.84% 5.98%
iRadimed 26.85%23.90%20.89%

Integer presently has a consensus price target of $113.67, indicating a potential downside of 10.25%. iRadimed has a consensus price target of $120.00, indicating a potential upside of 40.60%. Given iRadimed's stronger consensus rating and higher probable upside, analysts clearly believe iRadimed is more favorable than Integer.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Integer
0 Sell rating(s)
11 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.08
iRadimed
0 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
3.00

Summary

iRadimed beats Integer on 11 of the 16 factors compared between the two stocks.

How does iRadimed compare to Pulse Biosciences?

iRadimed (NASDAQ:IRMD) and Pulse Biosciences (NASDAQ:PLSE) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, earnings, valuation, profitability, dividends, institutional ownership, analyst recommendations and media sentiment.

iRadimed presently has a consensus target price of $120.00, suggesting a potential upside of 40.60%. Pulse Biosciences has a consensus target price of $66.60, suggesting a potential upside of 32.04%. Given iRadimed's stronger consensus rating and higher probable upside, equities research analysts plainly believe iRadimed is more favorable than Pulse Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
iRadimed
0 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
3.00
Pulse Biosciences
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.86

iRadimed has higher revenue and earnings than Pulse Biosciences. Pulse Biosciences is trading at a lower price-to-earnings ratio than iRadimed, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
iRadimed$83.81M13.03$22.48M$1.8745.64
Pulse Biosciences$350K10,599.61-$72.78M-$1.21N/A

iRadimed has a beta of 0.91, suggesting that its stock price is 9% less volatile than the broader market. Comparatively, Pulse Biosciences has a beta of 1.65, suggesting that its stock price is 65% more volatile than the broader market.

iRadimed has a net margin of 26.85% compared to Pulse Biosciences' net margin of -5,603.88%. iRadimed's return on equity of 23.90% beat Pulse Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
iRadimed26.85% 23.90% 20.89%
Pulse Biosciences -5,603.88%-77.88%-67.89%

In the previous week, Pulse Biosciences had 5 more articles in the media than iRadimed. MarketBeat recorded 7 mentions for Pulse Biosciences and 2 mentions for iRadimed. iRadimed's average media sentiment score of 1.79 beat Pulse Biosciences' score of 0.33 indicating that iRadimed is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
iRadimed
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive
Pulse Biosciences
0 Very Positive mention(s)
3 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

92.3% of iRadimed shares are owned by institutional investors. Comparatively, 77.0% of Pulse Biosciences shares are owned by institutional investors. 34.6% of iRadimed shares are owned by company insiders. Comparatively, 74.0% of Pulse Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

iRadimed beats Pulse Biosciences on 11 of the 16 factors compared between the two stocks.

How does iRadimed compare to TransMedics Group?

iRadimed (NASDAQ:IRMD) and TransMedics Group (NASDAQ:TMDX) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, valuation, dividends, profitability, risk, earnings, analyst recommendations and institutional ownership.

iRadimed has a net margin of 26.85% compared to TransMedics Group's net margin of 19.85%. iRadimed's return on equity of 23.90% beat TransMedics Group's return on equity.

Company Net Margins Return on Equity Return on Assets
iRadimed26.85% 23.90% 20.89%
TransMedics Group 19.85%13.30%4.93%

In the previous week, TransMedics Group had 14 more articles in the media than iRadimed. MarketBeat recorded 16 mentions for TransMedics Group and 2 mentions for iRadimed. iRadimed's average media sentiment score of 1.79 beat TransMedics Group's score of 0.61 indicating that iRadimed is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
iRadimed
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive
TransMedics Group
3 Very Positive mention(s)
0 Positive mention(s)
10 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

iRadimed has a beta of 0.91, meaning that its share price is 9% less volatile than the broader market. Comparatively, TransMedics Group has a beta of 2.14, meaning that its share price is 114% more volatile than the broader market.

TransMedics Group has higher revenue and earnings than iRadimed. TransMedics Group is trading at a lower price-to-earnings ratio than iRadimed, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
iRadimed$83.81M13.03$22.48M$1.8745.64
TransMedics Group$727.65M4.36$190.29M$3.6924.76

iRadimed presently has a consensus price target of $120.00, suggesting a potential upside of 40.60%. TransMedics Group has a consensus price target of $113.30, suggesting a potential upside of 23.99%. Given iRadimed's stronger consensus rating and higher possible upside, equities research analysts plainly believe iRadimed is more favorable than TransMedics Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
iRadimed
0 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
3.00
TransMedics Group
0 Sell rating(s)
7 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.42

92.3% of iRadimed shares are owned by institutional investors. Comparatively, 99.7% of TransMedics Group shares are owned by institutional investors. 34.6% of iRadimed shares are owned by insiders. Comparatively, 6.9% of TransMedics Group shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

iRadimed beats TransMedics Group on 10 of the 17 factors compared between the two stocks.

How does iRadimed compare to AxoGen?

AxoGen (NASDAQ:AXGN) and iRadimed (NASDAQ:IRMD) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, valuation, risk, institutional ownership, profitability, media sentiment and dividends.

80.3% of AxoGen shares are owned by institutional investors. Comparatively, 92.3% of iRadimed shares are owned by institutional investors. 2.4% of AxoGen shares are owned by insiders. Comparatively, 34.6% of iRadimed shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

AxoGen currently has a consensus target price of $57.92, indicating a potential upside of 3.55%. iRadimed has a consensus target price of $120.00, indicating a potential upside of 40.60%. Given iRadimed's stronger consensus rating and higher probable upside, analysts clearly believe iRadimed is more favorable than AxoGen.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
AxoGen
1 Sell rating(s)
2 Hold rating(s)
13 Buy rating(s)
0 Strong Buy rating(s)
2.75
iRadimed
0 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
3.00

iRadimed has lower revenue, but higher earnings than AxoGen. AxoGen is trading at a lower price-to-earnings ratio than iRadimed, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AxoGen$225.21M14.83-$15.70M-$0.65N/A
iRadimed$83.81M13.03$22.48M$1.8745.64

AxoGen has a beta of 1.21, indicating that its stock price is 21% more volatile than the broader market. Comparatively, iRadimed has a beta of 0.91, indicating that its stock price is 9% less volatile than the broader market.

iRadimed has a net margin of 26.85% compared to AxoGen's net margin of -11.96%. iRadimed's return on equity of 23.90% beat AxoGen's return on equity.

Company Net Margins Return on Equity Return on Assets
AxoGen-11.96% -5.35% -4.41%
iRadimed 26.85%23.90%20.89%

In the previous week, AxoGen had 5 more articles in the media than iRadimed. MarketBeat recorded 7 mentions for AxoGen and 2 mentions for iRadimed. iRadimed's average media sentiment score of 1.79 beat AxoGen's score of 0.31 indicating that iRadimed is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
AxoGen
0 Very Positive mention(s)
0 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
iRadimed
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive

Summary

iRadimed beats AxoGen on 12 of the 17 factors compared between the two stocks.

How does iRadimed compare to AtriCure?

AtriCure (NASDAQ:ATRC) and iRadimed (NASDAQ:IRMD) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, institutional ownership, dividends, earnings, profitability, media sentiment, analyst recommendations and risk.

iRadimed has a net margin of 26.85% compared to AtriCure's net margin of 2.52%. iRadimed's return on equity of 23.90% beat AtriCure's return on equity.

Company Net Margins Return on Equity Return on Assets
AtriCure2.52% 4.01% 3.03%
iRadimed 26.85%23.90%20.89%

AtriCure presently has a consensus price target of $62.30, indicating a potential upside of 9.61%. iRadimed has a consensus price target of $120.00, indicating a potential upside of 40.60%. Given iRadimed's stronger consensus rating and higher probable upside, analysts clearly believe iRadimed is more favorable than AtriCure.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
AtriCure
1 Sell rating(s)
4 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.58
iRadimed
0 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
3.00

99.1% of AtriCure shares are held by institutional investors. Comparatively, 92.3% of iRadimed shares are held by institutional investors. 4.0% of AtriCure shares are held by company insiders. Comparatively, 34.6% of iRadimed shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, AtriCure had 5 more articles in the media than iRadimed. MarketBeat recorded 7 mentions for AtriCure and 2 mentions for iRadimed. iRadimed's average media sentiment score of 1.79 beat AtriCure's score of 0.72 indicating that iRadimed is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
AtriCure
3 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
iRadimed
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive

iRadimed has lower revenue, but higher earnings than AtriCure. iRadimed is trading at a lower price-to-earnings ratio than AtriCure, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AtriCure$534.53M5.41-$11.45M$0.30189.47
iRadimed$83.81M13.03$22.48M$1.8745.64

AtriCure has a beta of 1.22, suggesting that its share price is 22% more volatile than the broader market. Comparatively, iRadimed has a beta of 0.91, suggesting that its share price is 9% less volatile than the broader market.

Summary

iRadimed beats AtriCure on 10 of the 16 factors compared between the two stocks.

Get iRadimed News Delivered to You Automatically

Sign up to receive the latest news and ratings for IRMD and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IRMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

IRMD vs. The Competition

MetriciRadimedHealthcare Equipment & Supplies IndustryHealthcare SectorNASDAQ Exchange
Market Cap$1.09B$5.95B$7.85B$12.17B
Dividend Yield0.94%1.69%2.46%4.41%
P/E Ratio45.5835.6832.9127.37
Price / Sales12.955.448.595.73
Price / Cash45.8523.9521.9322.50
Price / Book10.204.374.403.70
Net Income$22.48M$143.12M$3.52B$392.17M
7 Day Performance-2.42%-4.86%-5.34%-4.53%
1 Month Performance-3.89%-2.87%-3.61%-5.86%
1 Year Performance0.58%-0.76%0.01%-7.78%

iRadimed Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
IRMD
iRadimed
3.4181 of 5 stars
$84.84
-0.6%
$120.00
+41.4%
+1.2%$1.09B$83.81M45.58166
ITGR
Integer
1.0066 of 5 stars
$126.65
+0.1%
$113.67
-10.3%
+82.4%$4.31B$1.85B42.5111,000
PLSE
Pulse Biosciences
3.4342 of 5 stars
$54.22
-6.8%
$66.60
+22.8%
+250.3%$3.83B$350KN/A116
TMDX
TransMedics Group
3.6724 of 5 stars
$91.23
-2.7%
$113.30
+24.2%
-20.5%$3.16B$605.49M24.76898
AXGN
AxoGen
1.9046 of 5 stars
$50.52
-0.2%
$57.92
+14.7%
+137.5%$3.02B$225.21MN/A622

Related Companies and Tools


This page (NASDAQ:IRMD) was last updated on 11/16/2026 by MarketBeat.com Staff.
From Our Partners